Published in BMB Rep on August 01, 2015
Data for analysis of mannose-6-phosphate glycans labeled with fluorescent tags. Data Brief (2016) 0.80
Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr (2006) 2.97
Sorting of lysosomal proteins. Biochim Biophys Acta (2008) 2.86
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics (2004) 2.33
Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase. Nat Med (2005) 1.93
A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology (2003) 1.72
The alpha- and beta-subunits of the human UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase [corrected] are encoded by a single cDNA. J Biol Chem (2005) 1.55
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One (2007) 1.54
Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther (2009) 1.38
Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem J (2005) 1.24
Functions of the alpha, beta, and gamma subunits of UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase. J Biol Chem (2009) 1.24
Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology (2007) 1.22
Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet (2005) 1.16
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab (2008) 1.13
Domain 5 of the cation-independent mannose 6-phosphate receptor preferentially binds phosphodiesters (mannose 6-phosphate N-acetylglucosamine ester). Biochemistry (2007) 1.08
Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. Mol Genet Metab (2014) 1.04
Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol Genet Metab (2011) 1.00
Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction. Mol Genet Metab (2011) 1.00
New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond. Pediatr Endocrinol Rev (2014) 0.99
Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice. J Biol Chem (2004) 0.99
Glycosylation and functionality of recombinant β-glucocerebrosidase from various production systems. Biosci Rep (2013) 0.98
Carbohydrate recognition by the mannose-6-phosphate receptors. Curr Opin Struct Biol (2009) 0.98
Administration of a mixture of fungal glucosidases to a patient with type II glycogenosis (Pompe's disease). Pediatrics (1968) 0.97
A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes. Nat Biotechnol (2012) 0.96
Production in yeast of alpha-galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. Glycobiology (2002) 0.90
Enzyme replacement therapy for lysosomal storage diseases. Pediatr Endocrinol Rev (2012) 0.90
Treatment of lysosomal storage diseases: recent patents and future strategies. Recent Pat Endocr Metab Immune Drug Discov (2014) 0.90
Enzyme replacement in Pompe disease: an attempt with purified human acid alpha-glucosidase. Birth Defects Orig Artic Ser (1973) 0.90
Glycosylation and phosphorylation of arylsulfatase A. J Biol Chem (1994) 0.89
Production of human beta-hexosaminidase A with highly phosphorylated N-glycans by the overexpression of the Ogataea minuta MNN4 gene. Glycobiology (2009) 0.88
Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act. Orphanet J Rare Dis (2015) 0.87
Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneys. Mol Med (2012) 0.86
Increased mannosylphosphorylation of N-glycans by heterologous expression of YlMPO1 in glyco-engineered Saccharomyces cerevisiae for mannose-6-phosphate modification. J Biotechnol (2015) 0.85
The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable. Br J Haematol (2012) 0.82
Enzymes approved for human therapy: indications, mechanisms and adverse effects. BioDrugs (2015) 0.80
Strategies for Neoglycan conjugation to human acid α-glucosidase. Bioconjug Chem (2011) 0.79
Comparative study on mannose 6-phosphate residue contents of recombinant lysosomal enzymes. Mol Genet Metab (2014) 0.78
Enhanced sialylation and in vivo efficacy of recombinant human α-galactosidase through in vitro glycosylation. BMB Rep (2013) 0.77
Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein. Bioconjug Chem (2013) 0.76